Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease

Human Molecular Genetics

Volumn 23, Issue 16, 2014, Pages 4328-4344

  Hsiao, Han Yun ^a,d   Chiu, Feng Lan ^b   Chen, Chiung Mei ^e   Wu, Yih Ru ^e   Chen, Hui Mei ^a   Chen, Yu Chen ^a,d   Kuo, Hung Chih ^b,c   Chern, Yijuang ^a,d  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GLIAL FIBRILLARY ACIDIC PROTEIN; HUNTINGTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROPROTECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; XPRO 1595; CASPASE; CYTOKINE; LIPOPOLYSACCHARIDE; MUTANT PROTEIN; PROTEIN AGGREGATE; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; XENP 1595;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CAG REPEAT; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; FEMALE; GLIA; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; LONG TERM CARE; MALE; MICROGLIA; MOTOR PERFORMANCE; MOUSE; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; OSMOTIC MINIPUMP; PATHOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SIGNAL TRANSDUCTION; ANIMAL TISSUE; ASTROCYTE CULTURE; BRAIN CORTEX; CELL DENSITY; CORPUS STRIATUM; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; GLIOSIS; HTT GENE; IN VIVO STUDY; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; TREATMENT OUTCOME; ANIMAL; DRUG EFFECTS; HUNTINGTON DISEASE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; NERVE CELL; NEWBORN; PRIMARY CELL CULTURE; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; CELL SURVIVAL; CEREBRAL CORTEX; CORPUS STRIATUM; HUMANS; HUNTINGTON DISEASE; INFLAMMATION; INFUSIONS, INTRAVENTRICULAR; MICE; MICE, TRANSGENIC; NEURONS; PLURIPOTENT STEM CELLS; PRIMARY CELL CULTURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904742785     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu151     Document Type: Article

References (65)

1. Bjorkqvist, M., Wild, E.J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R.V., Benn, C.L., Soulet, D. et al. (2008) Anovel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med., 205, 1869-1877.
2. Hensley, K., Fedynyshyn, J., Ferrell, S., Floyd, R.A., Gordon, B., Grammas, P., Hamdheydari, L., Mhatre, M., Mou, S., Pye, Q.N. et al. (2003) Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis., 14, 74-80.
3. McCoy, M.K., Martinez, T.N., Ruhn, K.A., Szymkowski, D.E., Smith, C.G., Botterman, B.R., Tansey, K.E. and Tansey, M.G. (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci., 26, 9365-9375.
4. McGeer, P.L. and McGeer, E.G. (2002) Local neuroinflammation and the progression of Alzheimer's disease. J. Neurovirol., 8, 529-538.
5. Tai, Y.F., Pavese, N., Gerhard, A., Tabrizi, S.J., Barker, R.A., Brooks, D.J. and Piccini, P. (2007) Microglial activation in presymptomatic Huntington's disease gene carriers. Brain, 130, 1759-1766.
6. Hsiao, H.Y., Chen, Y.C., Chen, H.M., Tu, P.H. and Chern, Y. (2013) A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease. Hum. Mol. Genet., 22, 1826-1842.
7. Diguet, E., Rouland, R. and Tison, F. (2003) Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease. Ann. Neurol., 54, 841-842.
8. Hersch, S., Fink, K., Vonsattel, J.P. and Friedlander, R.M. (2003) Minocycline is protective in a mouse model of Huntington's disease. Ann. Neurol., 54, 841; author reply 842-843.
9. Smith, D.L., Woodman, B., Mahal, A., Sathasivam, K., Ghazi-Noori, S., Lowden, P.A., Bates, G.P. and Hockly, E. (2003) Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann. Neurol., 54, 186-196.
10. Wang, X., Zhu, S., Drozda, M., Zhang, W., Stavrovskaya, I.G., Cattaneo, E., Ferrante, R.J., Kristal, B.S. and Friedlander, R.M. (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA, 100, 10483-10487.
11. MacEwan, D.J. (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell. Signal., 14, 477-492.
12. Aggarwal, B.B. (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol., 3, 745-756.
13. Alexopoulou, L., Kranidioti, K., Xanthoulea, S., Denis, M., Kotanidou, A., Douni, E., Blackshear, P.J., Kontoyiannis, D.L. and Kollias, G. (2006) Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur. J. Immunol., 36, 2768-2780.
14. Arnett, H.A., Mason, J., Marino, M., Suzuki, K., Matsushima, G.K. and Ting, J.P. (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci., 4, 1116-1122.
15. Canault, M., Peiretti, F., Mueller, C., Kopp, F., Morange, P., Rihs, S., Portugal, H., Juhan-Vague, I. and Nalbone, G. (2004) Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis, 172, 211-218.
16. Aranguez, I., Torres, C. and Rubio, N. (1995)Thereceptor for tumor necrosis factor on murine astrocytes-enriched culture: characterization, intracellular degradation, and regulation by cytokines and Theiler's murine encephalomyelitis virus. Glia, 13, 185-194.
17. Botchkina, G.I., Meistrell, M.E. 3rd, Botchkina, I.L. and Tracey, K.J. (1997) Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol. Med., 3, 765-781.
18. Chung, C.Y., Seo, H., Sonntag, K.C., Brooks, A., Lin, L. and Isacson, O. (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet., 14, 1709-1725.
19. Lieberman, A.P., Pitha, P.M., Shin, H.S. and Shin,M.L. (1989) Production of tumor necrosis factor and other cytokines by astrocytes-enriched culture stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl. Acad. Sci. USA, 86, 6348-6352.
20. Morganti-Kossman, M.C., Lenzlinger, P.M., Hans, V., Stahel, P., Csuka, E., Ammann, E., Stocker, R., Trentz, O. and Kossmann, T. (1997) Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol. Psychiatry., 2, 133-136.
21. Selmaj, K.W. and Raine, C.S. (1995) Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology, 45, S44-849.
22. Tobinick, E., Gross, H., Weinberger, A. and Cohen, H. (2006) TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed, 8, 25.
23. Kim,S.Y. and Solomon, D.H. (2010)Tumornecrosis factor blockade and the risk of viral infection. Nat. Rev. Rheumatol., 6, 165-174.
24. Sfikakis, P.P. (2010) The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun., 11, 180-210.
25. Wallis, R.S. (2009) Infectious complications of tumor necrosis factor blockade. Curr. Opin. Infect. Dis., 22, 403-409.
26. Steed, P.M., Tansey, M.G., Zalevsky, J., Zhukovsky, E.A., Desjarlais, J.R., Szymkowski, D.E., Abbott, C., Carmichael, D., Chan, C., Cherry, L. et al. (2003) Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science, 301, 1895-1898.
27. Szymkowski, D.E. (2005) Creating the next generation of protein therapeutics through rational drug design. Curr. Opin. Drug Discov. Dev., 8, 590-600.
28. Zalevsky, J., Secher, T., Ezhevsky, S.A., Janot, L., Steed, P.M., O'Brien, C., Eivazi, A., Kung, J., Nguyen, D.H., Doberstein, S.K. et al. (2007) Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J. Immunol., 179, 1872-1883.
29. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
30. Carrier, R.L., Ma, T.C., Obrietan, K. and Hoyt, K.R. (2006) A sensitive and selective assay of neuronal degeneration in cell culture. J. Neurosci. Methods, 154, 239-244.
31. Khoshnan, A., Ko, J., Watkin, E.E., Paige, L.A., Reinhart, P.H. and Patterson, P.H. (2004) Activation of the IkappaB kinase complexand nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci., 24, 7999-8008.
32. Kielian, T. and Esen, N. (2004) Effects of neuroinflammation on glia-glia gap junctional intercellular communication: a perspective. Neurochem. Int., 45, 429-436.
33. Streit, W.J., Mrak, R.E. and Griffin, W.S. (2004) Microglia and neuroinflammation: a pathological perspective. J. Neuroinflammation, 1, 14.
34. Giralt, A., Carreton, O., Lao-Peregrin, C., Martin, E.D. and Alberch, J. (2011) Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol. Neurodegener., 6, 71.
35. Vonsattel, J.P. (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol., 115, 55-69.
36. Ju, T.C., Chen, H.M., Lin, J.T., Chang, C.P., Chang, W.C., Kang, J.J., Sun, C.P., Tao, M.H., Tu, P.H., Chang, C. et al. (2011) Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J. Cell. Biol., 194, 209-227.
37. Brambilla, R., Ashbaugh, J.J., Magliozzi, R., Dellarole, A., Karmally, S., Szymkowski, D.E. and Bethea, J.R. (2011) Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain, 134, 2736-2754.
38. McAlpine, F.E., Lee, J.K., Harms, A.S., Ruhn, K.A., Blurton-Jones, M., Hong, J., Das, P., Golde, T.E., LaFerla, F.M.,Oddo, S. et al. (2009) Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis., 34, 163-177.
39. Taoufik, E., Tseveleki, V., Chu, S.Y., Tselios, T., Karin, M., Lassmann, H., Szymkowski, D.E. and Probert, L. (2011) Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain, 134, 2722-2735.
40. Khoshnan, A. and Patterson, P.H. (2011) The role of IkappaB kinase complex in the neurobiology of Huntington's disease. Neurobiol. Dis., 43, 305-311.
41. Ho, A.K. and Hocaoglu, M.B. (2011) Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective. Clin. Genet., 80, 235-239.
42. Carvey, P.M., Zhao, C.H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B.S., Snyder, J., Zhu, Y.G. and Ling, Z.D. (2005) 6-Hydroxydopamineinduced alterations in blood-brain barrier permeability. Eur. J. Neurosci., 22, 1158-1168.
43. Pisani, V., Stefani, A., Pierantozzi, M., Natoli, S., Stanzione, P., Franciotta, D. and Pisani, A. (2012) Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J. Neuroinflammation, 9, 188.
44. Weiss, A., Trager, U., Wild, E.J., Grueninger, S., Farmer, R., Landles, C., Scahill, R.I., Lahiri, N., Haider, S., Macdonald, D. et al. (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J. Clin. Invest., 122, 3731-3736.
45. Kwan, W., Magnusson, A., Chou, A., Adame, A., Carson, M.J., Kohsaka, S., Masliah, E., Moller, T., Ransohoff, R., Tabrizi, S.J. et al. (2012) Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J. Neurosci., 32, 133-142.
46. Nayak, A., Ansar, R., Verma, S.K., Bonifati, D.M. and Kishore, U. (2011) Huntington's disease: an immune perspective. Neurol. Res. Int., 2011, 563784.
47. Kalonia, H., Kumar, P. and Kumar, A. (2010) Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease. Pharmacol. Biochem. Behav., 96, 115-124.
48. Kalonia, H. and Kumar, A. (2011) Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats. Life Sci., 88, 784-791.
49. Matsuki, S., Iuchi, Y., Ikeda, Y., Sasagawa, I., Tomita, Y. and Fujii, J. (2003) Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline. Biochem. Biophys. Res. Commun., 312, 843-849.
50. Wang, J., Wei, Q., Wang, C.Y., Hill, W.D., Hess, D.C. and Dong, Z. (2004) Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J. Biol. Chem., 279, 19948-19954.
51. Yrjanheikki, J., Tikka, T., Keinanen, R., Goldsteins, G., Chan, P.H. and Koistinaho, J. (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA, 96, 13496-13500.
52. Zhu, S., Stavrovskaya, I.G., Drozda, M., Kim, B.Y., Ona, V., Li, M., Sarang, S., Liu, A.S., Hartley, D.M., Wu, D.C. et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 417, 74-78.
53. Chen, M., Ona, V.O., Li, M., Ferrante, R.J., Fink, K.B., Zhu, S., Bian, J., Guo, L., Farrell, L.A., Hersch, S.M. et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med., 6, 797-801.
54. Mievis, S., Levivier, M., Communi, D., Vassart, G., Brotchi, J., Ledent, C. and Blum, D. (2007) Lack of minocycline efficiency in genetic models of Huntington's disease. Neuromol. Med., 9, 47-54.
55. Fromont, A., De Seze, J., Fleury, M.C., Maillefert, J.F. and Moreau, T. (2009) Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine, 45, 55-57.
56. Marchetti, L., Klein, M., Schlett, K., Pfizenmaier, K. and Eisel, U.L. (2004) Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem., 279, 32869-32881.
57. Shen, Y., Li, R. and Shiosaki, K. (1997) Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line. J. Biol. Chem., 272, 3550-3553.
58. Hurley, J.C., Tosolini, F.A. and Louis, W.J. (1991) Quantitative Limulus lysate assay for endotoxin and the effect of plasma. J. Clin. Pathol., 44, 849-854.
59. Chou, S.Y., Weng, J.Y., Lai, H.L., Liao, F., Sun, S.H., Tu, P.H., Dickson, D.W. and Chern, Y. (2008) Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J. Neurosci., 28, 3277-3290.
60. Huang, H.P., Chen, P.H., Hwu, W.L., Chuang, C.Y., Chien, Y.H., Stone, L., Chien, C.L., Li, L.T., Chiang, S.C., Chen, H.F. et al. (2011) Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum.Mol. Genet., 20, 4851-4864.
61. Chiang, M.C., Chen, H.M., Lee, Y.H., Chang, H.H., Wu, Y.C., Soong, B.W., Chen, C.M., Wu, Y.R., Liu, C.S., Niu, D.M. et al. (2007) Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. Hum. Mol. Genet., 16, 483-498.
62. Furuya, A., Asano, K., Shoji, N., Hirano, K., Hamasaki, T. and Suzaki, H. (2010) Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro. J. Inflamm. (Lond.), 7, 56.
63. Lin, J.T., Chang, W.C., Chen, H.M., Lai, H.L., Chen, C.Y., Tao, M.H. and Chern, Y. (2013) Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. Mol. Cell. Biol., 33, 1073-1084.
64. Granacher, U., Wolf, I., Wehrle, A., Bridenbaugh, S. and Kressig, R.W. (2010) Effects of muscle fatigue on gait characteristics under single and dual-task conditions in young and older adults. J. Neuroeng. Rehabil., 7, 56.
65. Riol-Blanco, L., Delgado-Martin, C., Sanchez-Sanchez, N., Alonso, C.L., Gutierrez-Lopez, M.D., Del Hoyo, G.M., Navarro, J., Sanchez-Madrid, F., Cabanas, C., Sanchez-Mateos, P. et al. (2009) Immunological synapse formation inhibits, via NF-kappaB and FOXO1, the apoptosis of dendritic cells. Nat. Immunol., 10, 753-760.